---
schema_version: "secwatch.filing_event.v1"
accession: "0001701541-25-000038"
form_type: "8-K"
ticker: "BDTX"
cik: "0001701541"
company_name: "Black Diamond Therapeutics, Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:47:35.626830+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Black Diamond Q3 net loss $8.5M, cash $135.5M; silevertinib Phase 2 ORR data due Q4 2025

## Summary
- Cash, cash equivalents and investments $135.5M as of Sept 30, 2025; funds operations into Q4 2027.
- Net loss $8.5M in Q3 2025 vs $15.6M in Q3 2024; R&D expenses fell to $7.4M from $12.9M.
- ORR and preliminary duration of treatment data from silevertinib Phase 2 in 1L non-classical EGFRm NSCLC expected later this quarter.
- PFS data from Phase 2 trial expected in H1 2026; company plans FDA feedback on registrational path.
- Exploring partnership opportunities for silevertinib in NSCLC and glioblastoma.

## SEC filing metadata
- accession: 0001701541-25-000038
- form_type: 8-K
- ticker: BDTX
- cik: 0001701541
- company_name: Black Diamond Therapeutics, Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701541/000170154125000038/0001701541-25-000038-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701541/000170154125000038/bdtx-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001701541-25-000038
- JSON: https://secwatch.observer/filing/0001701541-25-000038.json
- Plain text: https://secwatch.observer/filing/0001701541-25-000038.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.